Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Shionogi, Nagasaki University and MMV Secure JPY 910 Million GHIT Fund Support for Novel Malaria Prevention Drug Development

Fineline Cube Jul 13, 2026
Company Deals

Triastek Secures Strategic Financing to Advance 3D-Printed Oral Peptide Pipeline and Build Shanghai International R&D Center

Fineline Cube Jul 13, 2026
Company Deals

Takeda and Indonesian Government Launch $30 Million Plasma Ecosystem Initiative to Expand Access to Lifesaving Therapies

Fineline Cube Jul 13, 2026
Company Deals

InSilico Medicine Announces Strategic CNS Drug Discovery Collaboration with China Medical System, Eligible for RMB 1.2 Billion in Milestone Payments

Fineline Cube Jul 13, 2026
Company Deals

PegBio Partners with Rani Therapeutics on Oral Biologic Delivery Platform – Targeting Obesity and Metabolic Disease Candidates

Fineline Cube Jul 10, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Abbisko Therapeutics Secures FDA IND Clearance for Pan-KRAS Inhibitor ABSK211, Targeting Broad Spectrum of KRAS Alterations in Solid Tumors

Fineline Cube Jul 13, 2026
Company Drug

LongBio Pharma Secures FDA IND Approval for Novel Anti-IgE Antibody LP-003 in Peanut Allergy, Expanding Global Allergic Disease Pipeline

Fineline Cube Jul 13, 2026
Company Deals Digital

Mirxes Partners with XtalPi and Signet on AI-Driven Gastric Cancer System

Fineline Cube Feb 5, 2026

Mirxes Singapore (HKG: 2629) announced a partnership with XtalPi Inc. (QuantumPharm, HKG: 2228) and its...

Company Deals

Lishan Biopharma Licenses Evogene’s LS-LBP-002 for Global Oncology Development

Fineline Cube Feb 5, 2026

Shanghai Lishan Biopharmaceuticals Co., Ltd. announced a licensing agreement with Israel‑based Evogene Ltd. (NASDAQ: EVGN) for...

Company

Pfizer Revenue Drops 2% to $62.6B Amid COVID Decline, Non-COVID Portfolio Grows

Fineline Cube Feb 4, 2026

Pfizer Inc. (NYSE: PFE) reported full‑year 2025 revenue of USD 62.6 billion, representing a 2% operational decline at constant...

Others

Merck Keytruda Revenue Drives $65.5B Sales Despite Gardasil China Slump

Fineline Cube Feb 4, 2026

Merck & Co. (MSD, NYSE: MRK) reported full‑year 2025 revenue of USD 65.5 billion, up 2% year‑on‑year...

Company Drug

Hualan Biological’s HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial

Fineline Cube Feb 4, 2026

Hualan Biological Engineering Inc. (SHE: 002007) announced that the National Medical Products Administration (NMPA) has...

Company Deals

Bio-Thera Licenses Keytruda Biosimilar BAT3306 to Avalon for Middle East & North Africa

Fineline Cube Feb 4, 2026

Bio-Thera Solutions (SHA: 688177) announced a licensing agreement with Avalon Pharma, granting the Saudi Arabia‑headquartered...

Company Drug

Marubeni Launches Xenleta in China After Complex Licensing Journey

Fineline Cube Feb 4, 2026

Marubeni Pharmaceuticals (China) Co., Ltd. (formerly Sumitomo Pharma China) announced the initiation of commercialization for...

Company Drug

CMS-D017 Gets NMPA Approval for Complement-Mediated Kidney Disease Study

Fineline Cube Feb 4, 2026

China Medical System Holdings Limited (HKG: 0867) announced that the National Medical Products Administration (NMPA) has...

Company Deals Drug

Akeso Licenses Yixining to Jumpcan for PCSK9 Promotion in China

Fineline Cube Feb 4, 2026

Akeso Biopharma (HKG: 9926) announced a partnership with Jumpcan Pharmaceutical (SHA: 600566) granting Jumpcan exclusive...

Company Drug

United Laboratories UBT251 Gets NMPA Nod for Sleep Apnea Trial

Fineline Cube Feb 4, 2026

United Laboratories International Holdings Ltd (HKG: 3933) announced that the National Medical Products Administration (NMPA) has...

Company Drug

Wuhan YZY Biopharma Gets FDA Nod for M701 Phase Ib/II MPE Study

Fineline Cube Feb 4, 2026

Wuhan YZY Biopharma Co., Ltd (HKG: 2496) announced that the U.S. Food and Drug Administration...

Company

Amgen Q4 Revenue Grows 9% to $9.9B on Strong Product Sales

Fineline Cube Feb 4, 2026

Amgen (NASDAQ: AMGN) reported fourth‑quarter 2025 revenue of USD 9.9 billion, up 9% year‑over‑year (YOY), bringing full‑year revenue...

Company Deals

Grand Pharmaceutical to Acquire API Firms for RMB 316 Million

Fineline Cube Feb 4, 2026

Grand Pharmaceutical Group Limited (HKG: 0512) announced plans to acquire 100% equity in Hebei Grand...

Company

Novo Nordisk Sales Reach DKK 309 Billion on GLP‑1 and Obesity Surge

Fineline Cube Feb 4, 2026

Novo Nordisk (NYSE: NVO) reported 2025 global sales of DKK 309 billion (USD 48.9 billion), representing 10% year‑on‑year (YOY) growth...

Company Deals

Simcere Receives $40M Milestone from AbbVie for Trispecific Myeloma Drug

Fineline Cube Feb 4, 2026

Simcere Pharmaceutical Group Ltd (HKG: 2096) announced it has received a USD 40 million near‑term milestone payment from...

Company Deals

Medtronic to Acquire CathWorks for $585M, Expand AI-Based FFRangio System

Fineline Cube Feb 4, 2026

Medtronic Inc. (NYSE: MDT) announced it will exercise its option to acquire Israel-based medical device company...

Company Deals

TenNor Therapeutics Files Hong Kong IPO for Anti-Infective Pipeline

Fineline Cube Feb 4, 2026

TenNor Therapeutics (Suzhou) Limited submitted its initial public offering (IPO) application to the Main Board...

Company Drug

BeBetter Med BEBT-701 Approved for Hypertension siRNA Trial

Fineline Cube Feb 4, 2026

Guangzhou BeBetter Medicine Technology Co., Ltd. (SHA: 688759) announced that the National Medical Products Administration...

Company Drug

AbbVie Files Rinvoq for Vitiligo Approval in US and EU

Fineline Cube Feb 4, 2026

AbbVie (NYSE: ABBV) announced it has submitted new indication applications to the U.S. Food and Drug...

Company Drug

Datroway TNBC sBLA Gets FDA Priority Review for Triple-Negative Breast Cancer

Fineline Cube Feb 4, 2026

AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced that the U.S. Food and Drug Administration...

Posts pagination

1 … 74 75 76 … 693

Recent updates

  • Shionogi, Nagasaki University and MMV Secure JPY 910 Million GHIT Fund Support for Novel Malaria Prevention Drug Development
  • Triastek Secures Strategic Financing to Advance 3D-Printed Oral Peptide Pipeline and Build Shanghai International R&D Center
  • Abbisko Therapeutics Secures FDA IND Clearance for Pan-KRAS Inhibitor ABSK211, Targeting Broad Spectrum of KRAS Alterations in Solid Tumors
  • LongBio Pharma Secures FDA IND Approval for Novel Anti-IgE Antibody LP-003 in Peanut Allergy, Expanding Global Allergic Disease Pipeline
  • Pfizer and Astellas Secure FDA Approval for PADCEV-KEYTRUDA Combination as First Platinum-Free Neoadjuvant/Adjuvant Therapy for Muscle-Invasive Bladder Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Shionogi, Nagasaki University and MMV Secure JPY 910 Million GHIT Fund Support for Novel Malaria Prevention Drug Development

Company Deals

Triastek Secures Strategic Financing to Advance 3D-Printed Oral Peptide Pipeline and Build Shanghai International R&D Center

Company Drug

Abbisko Therapeutics Secures FDA IND Clearance for Pan-KRAS Inhibitor ABSK211, Targeting Broad Spectrum of KRAS Alterations in Solid Tumors

Company Drug

LongBio Pharma Secures FDA IND Approval for Novel Anti-IgE Antibody LP-003 in Peanut Allergy, Expanding Global Allergic Disease Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.